Featuring an interview with Dr William K Oh, including the following topics:

• Use of secondary hormonal agents for patients with metastatic hormone-sensitive prostate cancer (0:00)
• Data supporting the clinical activity of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (11:10)
• Radiopharmaceuticals for the treatment of mCRPC (16:53)
• Available data on cabozantinib for mCRPC (24:38)
• Cabozantinib combinations for advanced renal cell carcinoma (RCC) (26:17)
• Subcutaneous nivolumab versus intravenous nivolumab for advanced RCC (30:00)
• Addition of nivolumab to tivozanib compared to tivozanib alone in advanced relapsed/refractory RCC previously treated with an immune checkpoint inhibitor (31:28)
• Long-term follow-up with belzutifan for relapsed/refractory advanced RCC (33:39)
• Major findings from the NIAGARA study of perioperative durvalumab for muscle-invasive bladder cancer (MIBC) (35:44)
• Data surrounding adjuvant immunotherapy for MIBC (38:07)
• Clinical development of TAR-200 for high-risk non-muscle-invasive bladder cancer (39:44)
• Updated analysis of EV-302 study of enfortumab vedotin in combination with pembrolizumab for previously untreated advanced urothelial cancer (UC) (41:06)
• Implementation of emerging data in the treatment landscape of UC (41:56)

CME information and select publications